Assay for in Vivo Activated Protein C (apc) Activity

Period of Performance: 09/15/1994 - 03/14/1995


Phase 1 SBIR

Recipient Firm

Haematologic Technologies, Inc.
Essex Junction, VT 05452
Principal Investigator


In the area of clinical coagulation research, much attention is focused on the molecular events which occur before, during, and after anticoagulant and antithrombotic therapies. For purposes of monitoring the safety, efficacy and long-term effects of such therapies, there exist a number of commercially available assays to assess the progression of the procoagulant and fibrinolytic responses. For example, to monitor the procoagulant response, there exists: a) an assay for fragment 1-2 of prothrombin to monitor prothrombinase activity; and b) an assay for fibrinopeptide-A to monitor thrombin activity. The same holds true for the fibrinolytic response where assays for D-Dimer and FDP fragments of fibrin and fibrinogen respectively may be used to monitor the activity of plasmin. Unfortunately, an analogous assay to measure the progression of the anti-anticoagulant response does not exist. We propose that an assay to measure the in vivo activity of APC, by measuring the APC catalyzed inactivation of factor Va will provide a direct measure of the anticoagulant response. In this proposal we plan to develop an ELISA assay which may be used to quantitatively measure the APC catalyzed conversion of factor Va to factor Vai (inactivated factor Va).